Dateline City:
WHITEHOUSE STATION, N.J.
Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from a Phase 2b study evaluating two doses of
its investigational house dust mite sublingual immunotherapy tablet
(MK-8237). The data were presented for the first time during a
late-breaking oral session at the 2014 Annual Meeting of the American
Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more